Health Care

Armata CEO sells 14,041 shares to cover tax obligations amid a 66% yearly slump, yet FDA pediatric study plans signal long‑term growth prospects.

CEO insider buys at Elanco signal confidence: 2M+ shares acquired at near market price, high social buzz, and potential near‑term rally for investors.

CG Oncology insider James Mulay buys shares at one‑third the market price yet sells at a premium—insight into his confident, disciplined trading strategy and the company’s upside potential.

Insider selling at ANI: Cook Meredith’s structured 500‑share July sale shows routine trading, not panic—monitor Phase‑4 ILUVIEN results for future upside.

Insider buying at Agenus (AGUS) shows strong confidence amid a 45% weekly rally, new Phase 3 ROBBIN trial, and $340 M private placement—an insider‑backed catalyst for investors.

Glaukos CFO’s balanced buy‑sell trade shows confidence in the company’s rising valuation and hedges short‑term volatility while backing its glaucoma therapy future.

CEO Rosa David J.’s July 2026 Intuitive Surgical trades show insider confidence—buying after RSU vesting, selling at peak, and hinting at strong future earnings.

HealthEquity insider sale: Gathright sells 2,270 shares at $93.07—routine “sell‑to‑cover” amid rising platform earnings. Discover what this means for investors.

Oruka Insider Trading Insight: Arjun’s Rule 10b5‑1 moves mix strategic liquidity with long‑term confidence, revealing a disciplined approach to the biotech’s growth.

BridgeBio insiders buy low & sell high, signaling confidence in the gene‑editing pipeline and a potential rally ahead of key clinical data.